Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants
Haitao Liu(Harbin Medical University), Ge Liu(Heze Medical College), Jiangning Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Huan Yan(Wuhan University), Dongdong Hu, Jiao An, Yuanxiang Jiang, Chenliang Zhou, Jiadai Li, Xiayao Cao, Qianjun Zhu, Chuanqi Huang(Guangzhou University of Chinese Medicine), Longfei Ding(Shanghai Public Health Clinical Center), Dekui Wang(Northwest University), Yunqi Yang, Linlin Bao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuanfei Zhu(Shanghai Medical College of Fudan University), Chenyang Miao, Lingyun Zhou(Northeast Forestry University), Chao Zhang(Fudan University), Lingli Zhang, Youhua Xie(Shanghai Medical College of Fudan University), Zhongyu Hu(National Institutes for Food and Drug Control), Chenjian Gu(Washington University in St. Louis), Yuqiang Liu(Shenzhen Second People's Hospital), Pin Yü(Chinese Academy of Medical Sciences & Peking Union Medical College), Huachen Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yujiao Song, Jianqing Xu(Weifang Medical University)
Cited by 32
Related Papers
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
|Nature Medicine|2005|3.7k
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus
|eLife|2012|2.1k
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k